Moderna, Inc. $MRNA Shares Bought by Ethic Inc.

Ethic Inc. raised its position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 23.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,394 shares of the company’s stock after buying an additional 3,700 shares during the quarter. Ethic Inc.’s holdings in Moderna were worth $3,735,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Parallel Advisors LLC boosted its position in shares of Moderna by 8.8% during the 3rd quarter. Parallel Advisors LLC now owns 5,082 shares of the company’s stock valued at $979,000 after acquiring an additional 410 shares during the last quarter. Abacus Wealth Partners LLC bought a new stake in Moderna in the third quarter worth $259,000. Plancorp LLC bought a new stake in Moderna in the third quarter worth $210,000. May Hill Capital LLC purchased a new stake in Moderna during the third quarter valued at $238,000. Finally, Heritage Family Offices LLP purchased a new stake in Moderna during the third quarter valued at $253,000. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $250.83 on Wednesday. The company has a market capitalization of $101.49 billion, a price-to-earnings ratio of -35.33 and a beta of 1.16. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $280.80. The firm’s 50-day moving average is $196.68 and its 200 day moving average is $93.60. The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $1.48. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The firm’s quarterly revenue was up 29.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.51) earnings per share. Research analysts predict that Moderna, Inc. will post -5.69 EPS for the current year.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

  • Positive Sentiment: Moderna reported third-quarter revenue of about $1.3 billion, up 29% year over year and ahead of expectations, and raised its 2026 revenue-growth outlook to 15%–25%. Lower costs and respiratory-vaccine gains also supported the improved outlook. Why is Moderna stock soaring today?
  • Positive Sentiment: Investors also have a potential longer-term catalyst in personalized cancer vaccine intismeran. Phase 3 results reportedly showed a 42% reduction in melanoma recurrence or death, and Moderna is targeting an FDA filing by year-end 2026, which could lead to a decision in 2027. Can Moderna’s first cancer therapy win FDA approval in 2027?
  • Neutral Sentiment: Moderna is scheduled to present at the Jefferies Global Health Care Conference on November 18. The event could provide updates, but the announcement itself does not change the company’s outlook. Moderna to present at upcoming conference
  • Negative Sentiment: Despite the earnings beat, nearly all of Moderna’s revenue still comes from COVID-related products, leaving investors focused on the challenge of building durable sales beyond the pandemic market. That concern may weigh more heavily after the stock’s sharp recent run. Moderna’s Q3 numbers may not be enough to make the stock a buy
  • Negative Sentiment: Valuation is another headwind: Goldman Sachs raised its price target but kept a neutral rating, while a separate analysis put fair value well below the prevailing share price. Brookline also made modest reductions to its long-term earnings estimates, despite maintaining a Buy rating.

Insider Activity

In related news, President Stephen Hoge sold 40,294 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the completion of the sale, the president directly owned 1,525,858 shares of the company’s stock, valued at approximately $219,921,913.54. This trade represents a 2.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Argus upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a research report on Friday, August 28th. Rothschild & Co Redburn downgraded shares of Moderna from a “neutral” rating to a “sell” rating and boosted their target price for the stock from $40.00 to $81.00 in a report on Thursday, September 3rd. JPMorgan Chase & Co. upped their target price on shares of Moderna from $40.00 to $77.00 and gave the company an “underweight” rating in a research report on Friday, August 21st. Barclays increased their price target on shares of Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a report on Monday, August 24th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $305.00 price target (up from $230.00) on shares of Moderna in a research report on Monday. Six research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $113.75.

Check Out Our Latest Stock Analysis on Moderna

About Moderna

(Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Recommended Stories

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.